J. Bliss

发表

Is breast seroma after tumour resection associated with patient-reported breast appearance change following radiotherapy? Results from the IMPORT HIGH (CRUK/06/003) trial

C. Coles, E. Harris, C. Kirwan, 2019, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Women's Free-text Comments on their Quality of Life: An Exploratory Analysis from the UK Standardisation of Breast Radiotherapy (START) Trials for Early Breast Cancer

J. Haviland, J. Bliss, J. Mills, 2018, Clinical oncology (Royal College of Radiologists (Great Britain)).

Tamoxifen for early breast cancer: an overview of the randomised trials

Mike Clarke, Luc Bijnens, Michael Gnant, 1998, The Lancet.

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

Y Wang, Mike Clarke, Donald A. Berry, 2005, The Lancet.

Dissecting the heterogeneity of triple-negative breast cancer.

Paul Ellis, Christos Sotiriou, Sherene Loi, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A quantitative analysis of the spatial relationships of grouped microcalcifications demonstrated on xeromammography in benign and malignant breast disease.

D. Dance, D. Hansell, J. Bliss, 1988, The British journal of radiology.

A pooled analysis of bone marrow micrometastasis in breast cancer.

T. Fehm, R. Coombes, A. Vincent-Salomon, 2005, The New England journal of medicine.

Influence of delay in diagnosis on prognosis in testicular teratoma.

A. Horwich, M. Saunders, J. Bliss, 1989, British Journal of Cancer.

The influence of breast size on late radiation effects and association with radiotherapy dose inhomogeneity

J. Yarnold, R. A’Hern, J. Bliss, 1995 .

Plasma ESR1 Mutations and the Treatment of Estrogen Receptor-Positive Advanced Breast Cancer.

M. Dowsett, S. Loi, S. Loibl, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Serum thymidine kinase activity in patients with hormone receptor-positive and HER2-negative metastatic breast cancer treated with palbociclib and fulvestrant.

P. Neven, S. Loi, M. Piccart, 2022, European journal of cancer.

TPOAb and Thyroid Function Are Not Associated with Breast Cancer Outcome: Evidence from a Large-Scale Study Using Data from the Taxotere as Adjuvant Chemotherapy Trial (TACT, CRUK01/001)

P. Ellis, J. Bliss, P. Barrett-Lee, 2017, European Thyroid Journal.

The course of anxiety and depression over 5 years of follow-up and risk factors in women with early breast cancer: results from the UK Standardisation of Radiotherapy Trials (START).

J. Haviland, J. Bliss, J. Mills, 2010, Breast.

Fractionation sensitivity and dose response of late adverse effects in the breast after radiotherapy for early breast cancer: long-term results of a randomised trial.

Roger Owen, J. Yarnold, S. Bentzen, 2005, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Assessment of Molecular Relapse Detection in Early-Stage Breast Cancer.

M. Dowsett, S. Johnston, I. Smith, 2019, JAMA oncology.

Learning from the QUEST multicentre feasibility randomization trials in breast reconstruction after mastectomy

R. Horne, Z. Winters, C. Griffin, 2015, The British journal of surgery.

Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study

J. Peto, T. Treasure, D. Landau, 2011, The Lancet. Oncology.

The Mesothelioma and Radical Surgery Randomized Controlled Trial: The MARS Feasibility Study

J. Peto, T. Treasure, D. Landau, 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group.

Terry L. Smith, R. Collins, L. Holmberg, 1998, Lancet.

Epirubicin plus tamoxifen versus tamoxifen alone in node-positive postmenopausal patients with breast cancer: A randomized trial of the International Collaborative Cancer Group.

R. Coombes, J. Bliss, M. Marty, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prognostic and predictive value of ERβ1 and ERβ2 in the Intergroup Exemestane Study (IES)-first results from PathIES†.

P. Lønning, M. Cheang, V. Speirs, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

2LBA Fulvestrant Alone or with Concomitant Anastrozole Vs Exemestane Following Progression On Non-steroidal Aromatase Inhibitor – First Results of the SoFEa Trial (CRUKE/03/021 & CRUK/09/007) (ISRCTN44195747)

A. Howell, M. Dowsett, D. Cameron, 2012 .

Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor-positive locally advanced or metastatic breast cancer (SoFEA): a composite, multicentre, phase 3 randomised trial.

A. Howell, M. Dowsett, P. Ellis, 2013, The Lancet. Oncology.

The cost-effectiveness of adjuvant chemotherapy for early breast cancer: A comparison of no chemotherapy and first, second, and third generation regimens for patients with differing prognoses.

P. Ellis, A. Harris, M. Sculpher, 2011, European journal of cancer.

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

Ivanov, Harris, R. Collins, 2005, The Lancet.

Aromatase inhibitors versus tamoxifen in premenopausal women with oestrogen receptor-positive early-stage breast cancer treated with ovarian suppression: a patient-level meta-analysis of 7030 women from four randomised trials

J. Cuzick, J. Bergh, R. Peto, 2022, The Lancet. Oncology.

Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer in the randomised UK TACT2 trial (CRUK/05/19): a multicentre, phase 3, open-label, randomised, controlled trial

R. Laing, P. Ellis, H. Earl, 2017, The Lancet. Oncology.

Long-Term Follow-Up of the Intergroup Exemestane Study.

P. Lønning, L. Fallowfield, R. Paridaens, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials

E. Rutgers, E. Winer, J. Cuzick, 2015, The Lancet.

P. Lønning, J. Forbes, R. Paridaens, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Long-term endometrial effects in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES)—a randomised controlled trial of exemestane versus continued tamoxifen after 2–3 years tamoxifen

J. Jassem, R. C. Coombes, G. Bertelli, 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen.

J. Cuzick, J. Forbes, R. Peto, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Ovarian ablation or suppression in premenopausal early breast cancer: results from the international adjuvant breast cancer ovarian ablation or suppression randomized trial.

H. Earl, J. Peto, J. Yarnold, 2007, Journal of the National Cancer Institute.

Improving adjuvant chemotherapy in breast cancer -- can we get more for less with TACT2?

J. Bliss, P. Barrett-Lee, P. Canney, 2007, Clinical oncology (Royal College of Radiologists (Great Britain)).

Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women.

L. Gibson, J. Bliss, D. Lawrence, 2007, The Cochrane database of systematic reviews.

Aromatase inhibitors as adjuvant therapies in patients with breast cancer

R. Coombes, L. Gibson, E. Hall, 2003, The Journal of Steroid Biochemistry and Molecular Biology.

Duration of adjuvant chemotherapy; anthracyclines, taxanes and novel agents--more or less.

P. Ellis, J. Bliss, P. Barrett-Lee, 2002, Clinics in oncology.

TGFB1 polymorphisms are associated with risk of late normal tissue complications in the breast after radiotherapy for early breast cancer.

J. Yarnold, J. Overgaard, J. Alsner, 2005, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Impact of mutational profiles on response of primary oestrogen receptor-positive breast cancers to oestrogen deprivation

Christopher A. Miller, E. Mardis, M. Dowsett, 2016, Nature Communications.

The UK Standardisation of Breast Radiotherapy (START) Trial A of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial

J. Yarnold, J. Dewar, P. Hoskin, 2008, The Lancet. Oncology.

Abstract S3-01: The TNT trial: A randomized phase III trial of carboplatin (C) compared with docetaxel (D) for patients with metastatic or recurrent locally advanced triple negative orBRCA1/2breast cancer (CRUK/07/012)

N. Rahman, M. Dowsett, P. Ellis, 2015 .

Epirubicin dose and sequential hormonal therapy-Mature results of the HMFEC randomised phase III trial in premenopausal patients with node positive early breast cancer.

R. C. Coombes, J. Stebbing, J. Bliss, 2016, European journal of cancer.

Hypofractionated radiotherapy in early breast cancer: Clinical, dosimetric and radio-genomic issues.

J. Yarnold, N. Somaiah, J. Bliss, 2015, Breast.

Late normal tissue effects in the arm and shoulder following lymphatic radiotherapy: Results from the UK START (Standardisation of Breast Radiotherapy) trials

J. Yarnold, C. Griffin, J. Haviland, 2017, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Ipsilateral breast tumor relapse: local recurrence versus new primary tumor and the effect of whole-breast radiotherapy on the rate of new primaries.

J. Yarnold, J. Haviland, J. Bliss, 2011, International journal of radiation oncology, biology, physics.

Circulating tumour DNA analysis to direct therapy in advanced breast cancer (plasmaMATCH): a multicentre, multicohort, phase 2a, platform trial

H. Gevensleben, D. Rea, J. Braybrooke, 2020, The Lancet. Oncology.

Abstract S4-07: Effects of bisphosphonate treatment on recurrence and cause-specific mortality in women with early breast cancer: A meta-analysis of individual patient data from randomised trials

R. Gray, J. Bergh, T. Powles, 2013 .

Partial-breast radiotherapy after breast conservation surgery for patients with early breast cancer (UK IMPORT LOW trial): 5-year results from a multicentre, randomised, controlled, phase 3, non-inferiority trial

I. Ellis, P. Evans, M. Sculpher, 2017, The Lancet.

Prolongation of overall treatment time as a cause of treatment failure in early breast cancer: An analysis of the UK START (Standardisation of Breast Radiotherapy) trials of radiotherapy fractionation.

J. Yarnold, S. Bentzen, J. Haviland, 2016, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Quality of life after breast radiotherapy – Authors' reply

J. Yarnold, J. Haviland, J. Bliss, 2010 .

Test of association between variant tgβ1 alleles and late adverse effects of breast radiotherapy.

J. Yarnold, R. A’Hern, J. Haviland, 2010, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

19 Fractionation sensitivity of breast cancer. Results of a randomised trial

J. Yarnold, S. Bentzen, J. Bliss, 2003 .

Bone marrow micrometastases in early breast cancer–30-year outcome

R. Coombes, J. Bliss, J. Mansi, 2016, British Journal of Cancer.

Acute skin toxicity associated with a 1-week schedule of whole breast radiotherapy compared with a standard 3-week regimen delivered in the UK FAST-Forward Trial

J. Yarnold, C. Coles, N. Somaiah, 2016, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Genomic Instability and TP53 Genomic Alterations Associate With Poor Antiproliferative Response and Intrinsic Resistance to Aromatase Inhibitor Treatment

M. Dowsett, M. Cheang, J. Robertson, 2019, JCO precision oncology.

FFPE breast tumour blocks provide reliable sources of both germline and malignant DNA for investigation of genetic determinants of individual tumour responses to treatment

A. Rust, J. Yarnold, K. Fenwick, 2018, Breast Cancer Research and Treatment.

Adjuvant Palbociclib for Early Breast Cancer: The PALLAS Trial Results (ABCSG-42/AFT-05/BIG-14-03)

R. Greil, E. Winer, H. Rugo, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Combining fulvestrant (Faslodex) with continued oestrogen suppression in endocrine-sensitive advanced breast cancer: the SoFEA trial.

S. Johnston, D. Dodwell, J. Bliss, 2008, Clinical oncology (Royal College of Radiologists (Great Britain)).

In Regard to Vaidya et al.

J. Cuzick, S. Bentzen, J. Haviland, 2015, International journal of radiation oncology, biology, physics.

Radiotherapy for breast cancer, the TARGIT-A trial

T. Whelan, J. Haviland, J. Bliss, 2014, The Lancet.

Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women.

L. Gibson, J. Bliss, D. Lawrence, 2009, The Cochrane database of systematic reviews.

The Lancet Breast Cancer Commission: tackling a global health, gender, and equity challenge

J. Cuzick, Ruth Etzioni, R. Jagsi, 2022, The Lancet.

Reversal of skeletal effects of endocrine treatments in the intergroup exemestane study.

S. Cawthorn, J. Bliss, J. Fox, 2009 .

Intraoperative radiotherapy for early breast cancer

J. Haviland, J. Bliss, R. A'hern, 2010, The Lancet.

The effectiveness of the routine clinic visit in the follow-up of breast cancer patients: analysis of a defined patient cohort.

J. Yarnold, S. Ebbs, J. Bliss, 1998, Clinical oncology (Royal College of Radiologists (Great Britain)).

Road Map to Safe and Well-Designed De-escalation Trials of Systemic Adjuvant Therapy for Solid Tumors.

E. Winer, R. Gelber, M. Piccart, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The influence of breast size on late radiation effects and association with radiotherapy dose inhomogeneity.

J. Yarnold, R. A’Hern, J. Bliss, 1994, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Controlled release morphine tablets: a double‐blind trial in patients with advanced cancer

J. Bliss, G. Hanks, R. Twycross, 1987, Anaesthesia.

Carpal tunnel syndrome and musculoskeletal symptoms in postmenopausal women with early breast cancer treated with exemestane or tamoxifen after 2-3 years of tamoxifen: a retrospective analysis of the Intergroup Exemestane Study.

C. V. D. van de Velde, R. C. Coombes, J. Bliss, 2012, The Lancet. Oncology.

Long-term assessment of quality of life in the Intergroup Exemestane Study: 5 years post-randomisation

R. Coombes, L. Fallowfield, R. C. Coombes, 2012, British Journal of Cancer.

Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled study.

S. Cawthorn, R. C. Coombes, E. Hall, 2007, The Lancet. Oncology.

Phosphorylation of AKT pathway proteins is not predictive of benefit of taxane therapy in early breast cancer

I. Ellis, M. Dowsett, P. Ellis, 2013, Breast Cancer Research and Treatment.

HER2-enriched subtype and novel molecular subgroups drive aromatase inhibitor resistance and an increased risk of relapse in early ER+/HER2+ breast cancer

M. Dowsett, M. Cheang, D. Rea, 2022, EBioMedicine.

Accelerated partial breast irradiation: more questions than answers?

C. Coles, J. Bliss, P. Poortmans, 2019, The Lancet.

International Guidelines on Radiation Therapy for Breast Cancer During the COVID-19 Pandemic

R. Jagsi, I. Mjaaland, J. Bliss, 2020, Clinical Oncology.

Abstract S4-1: The UK START (Standardisation of Breast Radiotherapy) Trials: 10-year follow-up results

J. Yarnold, J. Dewar, P. Hoskin, 2012 .

Meta-analyses of visceral versus non-visceral metastatic hormone receptor-positive breast cancer treated by endocrine monotherapies

J. Robertson, R. Paridaens, S. Johnston, 2021, NPJ breast cancer.

Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials

Mike Clarke, Yasuo Ohashi, Michael Gnant, 2018, The Lancet. Oncology.

The impact of nausea and vomiting upon quality of life measures.

P. Selby, J. Bliss, B. Robertson, 1992, The British journal of cancer. Supplement.

Assessment of microtubule-associated protein (MAP)-Tau expression as a predictive and prognostic marker in TACT; a trial assessing substitution of sequential docetaxel for FEC as adjuvant chemotherapy for early breast cancer

I. Ellis, M. Dowsett, A. Tutt, 2014, Breast Cancer Research and Treatment.

Relationship between ER expression by IHC or mRNA with Ki67 response to aromatase inhibition: a POETIC study

M. Dowsett, M. Cheang, E. Mallon, 2022, Breast cancer research : BCR.

ESR1 Mutations and Overall Survival on Fulvestrant versus Exemestane in Advanced Hormone Receptor–Positive Breast Cancer: A Combined Analysis of the Phase III SoFEA and EFECT Trials

M. Dowsett, M. Piccart, J. Robertson, 2020, Clinical Cancer Research.

The late effects of cis-platinum on renal function.

A. Horwich, J. Bliss, C. Hamilton, 1989, European journal of cancer & clinical oncology.

PREDICT underestimates survival of patients with HER2-positive early-stage breast cancer

M. Piccart, M. Paesmans, L. Ameye, 2022, npj Breast Cancer.

4-Hydroxyandrostenedione in the prophylaxis of N-methyl-N-nitrosourea induced mammary tumourigenesis.

M. Dowsett, D. Easton, R. Coombes, 1991, British Journal of Cancer.

Effect of Metformin vs Placebo on Invasive Disease-Free Survival in Patients With Breast Cancer: The MA.32 Randomized Clinical Trial.

Bingshu E. Chen, T. Whelan, K. Gelmon, 2022, JAMA.

Idoxifene is equipotent to tamoxifen in inhibiting mammary carcinogenesis but forms lower levels of hepatic DNA adducts.

R. Coombes, D. Phillips, A. Hewer, 1997, British Journal of Cancer.

Evidence-based guidelines for managing patients with primary ER+ HER2− breast cancer deferred from surgery due to the COVID-19 pandemic

M. Ellis, M. Dowsett, J. Robertson, 2020, npj Breast Cancer.

Conducting non-commercial international clinical trials: the ICR-CTSU experience

J. Bliss, C. Snowdon, Lisa Fox, 2017, Trials.

Second cancer risk and mortality in men treated with radiotherapy for stage I seminoma

D. Dearnaley, A. Horwich, R. Huddart, 2013, British Journal of Cancer.

Adjuvant Hormone Therapy May Improve Survival in Epithelial Ovarian Cancer: Results of the AHT Randomized Trial

R. Eeles, H. Kitchener, M. Gore, 2016 .

Risk of second cancers among a cohort of 2,703 long-term survivors of testicular seminoma treated with radiotherapy.

A. Horwich, E. Hall, J. Bliss, 2010 .

Fighting spirit in patients with cancer

M. Watson, J. Haviland, J. Bliss, 2000, The Lancet.

High dose chemotherapy and autologous stem cell transplantation as adjuvant therapy for primary breast cancer patients with four or more lymph nodes involved: long-term results of an international randomised trial.

A. Howell, R. Coombes, A. Tres, 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

Impact of Duration of Neoadjuvant Aromatase Inhibitors on Molecular Expression Profiles in Estrogen Receptor–positive Breast Cancers

M. Dowsett, J. Parker, M. Cheang, 2021, Clinical cancer research : an official journal of the American Association for Cancer Research.

Patient-level meta-analysis of randomized trials of aromatase inhibitors (AI) versus tamoxifen (Tam).

J. Cuzick, J. Forbes, M. Dowsett, 2014 .

Early closure of a randomized controlled trial of three treatment approaches to early localised prostate cancer: the MRC PR06 trial

Srinivasan, P. Fayers, M. Sydes, 2004, BJU international.

Biomarkers of Response and Resistance to Palbociclib Plus Letrozole in Patients With ER+/HER2− Breast Cancer

M. Dowsett, M. Cheang, K. Pogue-Geile, 2021, Clinical Cancer Research.

FAST Phase III RCT of Radiotherapy Hypofractionation for Treatment of Early Breast Cancer: 10-Year Results (CRUKE/04/015)

J. Yarnold, J. Haviland, J. Bliss, 2018, International Journal of Radiation Oncology, Biology, Physics.

Design and Rationale of a Randomised Comparison of Cyclophosphamide, Methotrexate and Fluorouracil vs Fluorouracil, Epirubicin and Cyclophosphamide in Node-Positive Premenopausal Women with Operable Breast Cancer

R. Coombes, J. Bliss, M. Marty, 2012, Drugs.

Prospective observational study of breast cancer treatment outcomes for UK women aged 18-40 years at diagnosis: the POSH study.

D. Altman, D. Eccles, E. Copson, 2013, Journal of the National Cancer Institute.

The Impact of Radiotherapy Dose on Local Control of Ewing's Sarcoma of Bone

N. Burnet, J. Bliss, C. Harmer, 1997, Sarcoma.

OC-0595: FAST-Forward phase 3 RCT of 1-week hypofractionated breast radiotherapy:3-year normal tissue effects

E. Sawyer, J. Yarnold, C. Coles, 2018 .

Cediranib in patients with alveolar soft-part sarcoma (CASPS): a double-blind, placebo-controlled, randomised, phase 2 trial

I. Judson, B. Seddon, M. Tattersall, 2019, The Lancet. Oncology.

Risk of acute myeloid leukemia and myelodysplastic syndrome in trials of adjuvant epirubicin for early breast cancer: correlation with doses of epirubicin and cyclophosphamide.

J. Bergh, M. Piccart, R. Coombes, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Adjuvant cyclophosphamide, methotrexate, and fluorouracil versus fluorouracil, epirubicin, and cyclophosphamide chemotherapy in premenopausal women with axillary node-positive operable breast cancer: results of a randomized trial. The International Collaborative Cancer Group.

M. Espié, D. Amadori, R. Coombes, 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Cost-effectiveness of 5 fraction and partial breast radiotherapy for early breast cancer in the UK: model-based multi-trial analysis

R. Faria, J. Yarnold, C. Coles, 2022, Breast Cancer Research and Treatment.

A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer*

P. Lønning, L. Fallowfield, L. Gibson, 2004, The New England journal of medicine.

Reversal of skeletal effects of endocrine treatments in the Intergroup Exemestane Study

S. Cawthorn, R. C. Coombes, J. Bliss, 2010, Breast Cancer Research and Treatment.

Safety of exemestane in the Intergroup Exemestane Study.

R. Coombes, E. Hall, J. Bliss, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Adjuvant psychological therapy for patients with cancer: Outcome at one year

M. Watson, J. Bliss, S. Greer, 1994 .

ATARI trial: ATR inhibitor in combination with olaparib in gynecological cancers with ARID1A loss or no loss (ENGOT/GYN1/NCRI)

S. Lheureux, R. Natrajan, C. Lord, 2021, International Journal of Gynecological Cancer.

First mature analysis of the Intergroup Exemestane Study.

R. Paridaens, T. Delozier, C. V. D. van de Velde, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

How informed is declared altruism in clinical trials? A qualitative interview study of patient decision-making about the QUEST trials (Quality of Life after Mastectomy and Breast Reconstruction)

R. Horne, Z. Winters, C. Griffin, 2016, Trials.

The growth rate of metastatic nonseminomatous germ cell testicular tumours measured by marker production doubling time--II. Prognostic significance in patients treated by chemotherapy.

A. Horwich, J. Bliss, P. Price, 1990, European journal of cancer.

Exploring the role and function of trial steering committees: results of an expert panel meeting

P. Sandercock, S. Lewis, M. Sydes, 2015, Trials.

Exploring the role and functionality of trial steering committees

P. Sandercock, S. Lewis, M. Sydes, 2015, Trials.

The Application and Feasibility of Using Routine Data Sources for Long-term Cancer Clinical Trial Follow-up.

C. Griffin, I. Bhattacharya, J. Bliss, 2017, Clinical oncology (Royal College of Radiologists (Great Britain)).

A randomized trial comparing adjuvant fluorouracil, doxorubicin, and mitomycin with no treatment in operable gastric cancer. International Collaborative Cancer Group.

D. Amadori, R. Coombes, P. Schein, 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Risk of cutaneous melanoma associated with a family history of the disease

S. Franceschi, D. Easton, J. Peto, 1995, International journal of cancer.

Morphine and dryness of the mouth.

J. Bliss, P. Hoskin, G. Hanks, 1989, BMJ.

A randomised trial of accelerated radiotherapy for localised invasive bladder cancer.

D. Dearnaley, A. Horwich, R. Huddart, 2005, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Prognostic implications of perineural spread in squamous carcinomas of the head and neck

K. Soo, C. O'brien, J. Bliss, 1986, The Laryngoscope.

Comparison of patient reported quality of life and impact of treatment side effects experienced with a taxane-containing regimen and standard anthracycline based chemotherapy for early breast cancer: 6 year results from the UK TACT trial (CRUK/01/001)

P. Ellis, D. Cameron, E. Hall, 2014, European journal of cancer.

Risk of second brain tumour after conservative surgery and radiotherapy for pituitary adenoma.

J. Bliss, S. Ashley, D. Ford, 1992, BMJ.

Radical neck dissections for squamous carcinomas: pathological findings and their clinical implications with particular reference to transcapsular spread.

K. Soo, C. O'brien, J. Bliss, 1987, International journal of radiation oncology, biology, physics.

Risk of cutaneous melanoma associated with pigmentation characteristics and freckling: Systematic overview of 10 case‐control studies

D. Easton, J. Peto, T. Mack, 1995 .

Excision margins in high-risk malignant melanoma.

J. Thomas, R. A’Hern, J. Bliss, 2004, The New England journal of medicine.

Gastrointestinal morbidity of adjuvant radiotherapy in stage I malignant teratoma of the testis.

A. Horwich, J. Bliss, M. Peckham, 1987, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Carboplatin in the combination chemotherapy of non-seminomatous germ cell tumours.

A. Horwich, J. Bliss, 1996, Annals of oncology : official journal of the European Society for Medical Oncology.

Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials

Bingshu E. Chen, D. Berry, P. Fasching, 2019, The Lancet.

Randomised single centre double-blind placebo controlled phase II trial of Tocovid SupraBio in combination with pentoxifylline in patients suffering long-term gastrointestinal adverse effects of radiotherapy for pelvic cancer: the PPALM study.

J. Yarnold, L. Gothard, J. Bliss, 2022, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Assessment of structural chromosomal instability phenotypes as biomarkers of carboplatin response in triple negative breast cancer: the TNT trial

A. Tutt, A. Tutt, N. Orr, 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

Assessment of structural chromosomal instability phenotypes as biomarkers of carboplatin response in the TNT trial

M. Cheang, A. Tutt, S. Pinder, 2020 .

Homologous recombination DNA repair deficiency and PARP inhibition activity in primary triple negative breast cancer

M. Dowsett, S. Nik-Zainal, A. Tutt, 2020, Nature Communications.

Genomic and Transcriptomic Analyses of Breast Cancer Primaries and Matched Metastases in AURORA, the Breast International Group (BIG) Molecular Screening Initiative

R. Greil, C. Sotiriou, S. Loi, 2021, Cancer discovery.

The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trials.

Joanne S Haviland, John R Yarnold, J. Yarnold, 2013, The Lancet. Oncology.

Early circulating tumor DNA dynamics and clonal selection with palbociclib and fulvestrant for breast cancer

M. Koehler, Xin Huang, M. Cristofanilli, 2018, Nature Communications.

Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial

Paul Ellis, Nazneen Rahman, Alexander Gutin, 2018, Nature Medicine.

Early circulating tumor DNA dynamics and clonal selection with palbociclib and fulvestrant for breast cancer

M. Koehler, Xin Huang, M. Cristofanilli, 2018, Nature Communications.

The UK Standardisation of Breast Radiotherapy (START) Trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial

J R Yarnold, J. Yarnold, J. Dewar, 2008, The Lancet.

Long-term outcome and prognostic value of Ki67 after perioperative endocrine therapy in postmenopausal women with hormone-sensitive early breast cancer (POETIC): an open-label, multicentre, parallel-group, randomised, phase 3 trial

M. Dowsett, M. Cheang, E. Mallon, 2020, The Lancet. Oncology.

Targeted radiotherapy for early breast cancer – Authors' reply

J. Yarnold, C. Coles, M. Wilcox, 2018, The Lancet.

Comparison of patient-reported breast, arm, and shoulder symptoms and body image after radiotherapy for early breast cancer: 5-year follow-up in the randomised Standardisation of Breast Radiotherapy (START) trials.

J. Yarnold, J. Haviland, J. Bliss, 2010, The Lancet. Oncology.

Wide versus narrow excision margins for high-risk, primary cutaneous melanomas: long-term follow-up of survival in a randomised trial

J. Thomas, J. Bliss, J. Newton-Bishop, 2016, The Lancet. Oncology.

Long term follow up of survival in a randomised trial of wide or narrow excision margins in high risk primary melanoma.

R. A’Hern, J. Bliss, J. Newton-Bishop, 2015 .

Heterogeneity in global gene expression profiles between biopsy specimens taken peri-surgically from primary ER-positive breast carcinomas

M. Dowsett, J. Parker, M. Cheang, 2016, Breast Cancer Research.

Effect of human recombinant tumour necrosis factor and rat gamma interferon on nitrosomethylurea-induced mammary tumours.

R. Coombes, J. Bliss, P. H. van der Meide, 1989, British Journal of Cancer.

5010 Survival and safety post study treatment completion: an updated analysis of the Intergroup Exemestane Study (IES) – submitted on behalf of the IES Investigators

J. Bliss, C. Snowdon, L. Kilburn, 2009 .

Ten-year survival of neoadjuvant dual HER2 blockade in patients with HER2-positive breast cancer.

R. Gelber, M. Piccart, H. Gómez, 2022, European journal of cancer.

Impact of aromatase inhibitor treatment on global gene expression and its association with antiproliferative response in ER+ breast cancer in postmenopausal patients

M. Dowsett, M. Cheang, E. Mallon, 2019, Breast Cancer Research.

Quality of life in the intergroup exemestane study: a randomized trial of exemestane versus continued tamoxifen after 2 to 3 years of tamoxifen in postmenopausal women with primary breast cancer.

R. Coombes, L. Fallowfield, E. Hall, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Biomarker-guided trials: Challenges in practice

J. Wason, R. Kolamunnage-Dona, J. Bliss, 2019, Contemporary clinical trials communications.

How do patients want to learn of results of clinical trials? A survey of 1431 breast cancer patients

J. Bliss, P. Barrett-Lee, P. Ellis, 2007, British Journal of Cancer.

Abstract S6-01:BRCA1methylation status, silencing and treatment effect in the TNT trial: A randomized phase III trial of carboplatin compared with docetaxel for patients with metastatic or recurrent locally advanced triple negative or BRCA1/2 breast cancer (CRUK/07/012)

A. Ashworth, C. Perou, N. Rahman, 2017 .

Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trial

E. Sawyer, J. Yarnold, C. Coles, 2020, The Lancet.

Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13 864 women in seven randomised trials

J. Cuzick, J. Bergh, R. Peto, 2021, The Lancet. Oncology.

Association of tumor angiogenesis with bone marrow micrometastases in breast cancer patients.

S. Fox, A. Harris, B. Gusterson, 1997, Journal of the National Cancer Institute.

Cellular radiosensitivity and complication risk after curative radiotherapy.

J. Yarnold, J. Eady, J. Peacock, 2000, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Genomic profile of advanced breast cancer in circulating tumour DNA

J. Reis-Filho, M. Hubank, A. Wardley, 2021, Nature Communications.

Exploration of tumour-infiltrating lymphocytes as a predictive biomarker for adjuvant endocrine therapy in early breast cancer

H. Putter, P. Kuppen, C. V. D. van de Velde, 2018, Breast Cancer Research and Treatment.

Vitamin D Receptor Gene Polymorphisms and Breast Cancer Risk

M. Guy, J. Bliss, J. Mansi, 2004, Clinical Cancer Research.

Effect of radiotherapy fraction size on tumour control in patients with early-stage breast cancer after local tumour excision: long-term results of a randomised trial.

John R Yarnold, J. Yarnold, S. Bentzen, 2006, The Lancet. Oncology.

Abiraterone in patients with recurrent epithelial ovarian cancer: principal results of the phase II Cancer of the Ovary Abiraterone (CORAL) trial (CRUK – A16037)

M. Dowsett, N. Tunariu, S. Kaye, 2020, Therapeutic advances in medical oncology.

Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open-label, phase III, randomised controlled trial

I. Ellis, M. Dowsett, P. Ellis, 2009, The Lancet.

Human epidermal growth factor receptor 2 status correlates with lymph node involvement in patients with estrogen receptor (ER) negative, but with grade in those with ER-positive early-stage breast cancer suitable for cytotoxic chemotherapy.

I. Ellis, M. Dowsett, P. Ellis, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

When the World Throws You a Curve Ball: Lessons Learned in Breast Cancer Management.

C. Coles, A. Kirby, J. Haviland, 2021, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

Randomized Phase II Study Evaluating Palbociclib in Addition to Letrozole as Neoadjuvant Therapy in Estrogen Receptor-Positive Early Breast Cancer: PALLET Trial.

M. Dowsett, T. Julian, M. Cheang, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

NEOCENT: a randomised feasibility and translational study comparing neoadjuvant endocrine therapy with chemotherapy in ER-rich postmenopausal primary breast cancer

Sung-Bae Kim, M. Cheang, R. Coombes, 2014, Breast Cancer Research and Treatment.

Evidence-based guidelines for managing patients with primary ER+ HER2− breast cancer deferred from surgery due to the COVID-19 pandemic

M. Ellis, M. Dowsett, J. Robertson, 2020, npj Breast Cancer.

Breast cancer in older women: trials and tribulations.

P. Ellis, M. Reed, J. Bliss, 2009, Clinical oncology (Royal College of Radiologists (Great Britain)).

Endocrine therapy, new biologicals, and new study designs for presurgical studies in breast cancer.

Mitch Dowsett, Helen Anderson, Roger A'Hern, 2011, Journal of the National Cancer Institute. Monographs.

Efficacy of everolimus in patients with HR+/HER2- high risk early stage breast cancer

J. Lemonnier, M. Campone, D. Cameron, 2021 .

Updated Standardized Definitions for Efficacy End Points (STEEP) in Adjuvant Breast Cancer Clinical Trials: STEEP Version 2.0

E. Winer, J. Foster, N. Tung, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Dissecting the predictive value of MAPK/AKT/estrogen-receptor phosphorylation axis in primary breast cancer to treatment response for tamoxifen over exemestane: a Translational Report of the Intergroup Exemestane Study (IES)—PathIES

M. Cheang, Simak Ali, W. Zwart, 2019, Breast Cancer Research and Treatment.

Abstract P1-13-03: Mature analysis of UK Taxotere as Adjuvant Chemotherapy (TACT) trial (CRUK 01/001); effects of treatment and characterisation of patterns of breast cancer relapse.

M. Dowsett, H. Earl, J. Yarnold, 2012 .

Can routine data be used to support cancer clinical trials? A historical baseline on which to build: retrospective linkage of data from the TACT (CRUK 01/001) breast cancer trial and the National Cancer Data Repository

P. Ellis, M. Aresu, J. Bliss, 2017, Trials.

Abstract GS4-05: Dose escalated simultaneous integrated boost radiotherapy for women treated by breast conservation surgery for early breast cancer: 3-year adverse effects in the IMPORT HIGH trial (CRUK/06/003)

J. Yarnold, C. Coles, M. Wilcox, 2019, General Session Abstracts.

Abstract P5-10-06: TACT2 Randomised Adjuvant Trial in Early Breast Cancer (EBC): Tolerability and Toxicity of Standard 3 Weekly Epirubicin (E) Versus Accelerated Epirubicin (aE) in 129 UK Hospitals (4391 Patients) (CRUK/05/019)

D. Cameron, A. Wardley, G. Bertelli, 2010 .

PREDICT underestimates survival of patients with HER2-positive early-stage breast cancer

M. Piccart, M. Paesmans, L. Ameye, 2022, npj Breast Cancer.

Adjuvant chemotherapy in T3 carcinoma of the bladder. A prospective trial: preliminary report.

H. Bloom, A. Horwich, J. Bliss, 1988, British journal of urology.

Adjuvant Hormone Therapy May Improve Survival in Epithelial Ovarian Cancer: Results of the AHT Randomized Trial.

R. Eeles, H. Kitchener, M. Gore, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Chemotherapy for malignant melanoma: combinations and high doses produce more responses without survival benefit.

S. Lakhani, M. Gore, P. Selby, 1990, British Journal of Cancer.

Ten-Year Results of FAST: A Randomized Controlled Trial of 5-Fraction Whole-Breast Radiotherapy for Early Breast Cancer

J. Yarnold, J. Haviland, J. Bliss, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Patient-Reported Outcomes Over 5 Years After Whole- or Partial-Breast Radiotherapy: Longitudinal Analysis of the IMPORT LOW (CRUK/06/003) Phase III Randomized Controlled Trial

J. Yarnold, C. Coles, C. Kirwan, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

It's PRIMETIME. Postoperative Avoidance of Radiotherapy: Biomarker Selection of Women at Very Low Risk of Local Recurrence.

C. Coles, C. Kirwan, J. Bliss, 2016, Clinical oncology (Royal College of Radiologists (Great Britain)).

Effect of Celecoxib vs Placebo as Adjuvant Therapy on Disease-Free Survival Among Patients With Breast Cancer: The REACT Randomized Clinical Trial.

C. Denkert, A. Makris, J. Bartlett, 2021, JAMA oncology.

Impact of Selenium on Mood and Quality of Life: A Randomized, Controlled Trial

M. Warren-Perry, J. Bliss, A. Thompson, 2006, Biological Psychiatry.

The Mini-MAC: Further Development of the Mental Adjustment to Cancer Scale

M. Watson, J. Bliss, S. Greer, 1994 .

Abstract GS3-07: The genomic landscape of breast cancer based on ctDNA analysis: Data from the plasmaMATCH trial

M. Hubank, A. Wardley, R. Roylance, 2020 .

Abstract GS3-06: Results from the plasmaMATCH trial: A multiple parallel cohort, multi-centre clinical trial of circulating tumour DNA testing to direct targeted therapies in patients with advanced breast cancer (CRUK/15/010)

D. Rea, J. Braybrooke, D. Cameron, 2020 .

Pitfalls in placebo-controlled trials in palliative care: dexamethasone for the palliation of malignant bowel obstruction

M. Gore, G. Hanks, R. A’Hern, 1998, Palliative medicine.

Increasing the dose density of adjuvant chemotherapy by shortening intervals between courses or by sequential drug administration significantly reduces both disease recurrence and breast cancer mortality: An EBCTCG meta-analysis of 21,000 women in 16 randomised trials

J. Bergh, R. Peto, L. Norton, 2018 .

Heterozygosity for mutations in the ataxia telangiectasia gene is not a major cause of radiotherapy complications in breast cancer patients.

S. Seal, M. Stratton, N. Rahman, 1998, British Journal of Cancer.

Meta-analyses of visceral versus non-visceral metastatic hormone receptor-positive breast cancer treated by endocrine monotherapies

R. Paridaens, S. Chia, I. Bradbury, 2021, npj Breast Cancer.

Abstract P2-14-01: Fulvestrant vs exemestane for treatment of metastatic breast cancer in patients with acquired resistance to non-steroidal aromatase inhibitors – a meta-analysis of EFECT and SoFEA (CRUKE/03/021 & CRUK/09/007)

A. Howell, M. Dowsett, M. Piccart, 2012 .

Plasma 25-hydroxy vitamin D concentrations, vitamin D receptor genotype and breast cancer risk in a UK Caucasian population.

M. Guy, J. Bliss, J. Mansi, 2005, European journal of cancer.

XRCC1 Polymorphism Associated With Late Toxicity After Radiation Therapy in Breast Cancer Patients.

J. Chang-Claude, J. Debus, A. Dunning, 2015, International journal of radiation oncology, biology, physics.

Further development of a quality of life measure for cancer patients: The rotterdam symptom checklist (revised)

T. Ibbotson, J. Bliss, M. Watson, 1992 .

Do Patient-reported Outcome Measures Agree with Clinical and Photographic Assessments of Normal Tissue Effects after Breast Radiotherapy? The Experience of the Standardisation of Breast Radiotherapy (START) Trials in Early Breast Cancer.

J. Yarnold, J. Haviland, J. Bliss, 2016, Clinical oncology (Royal College of Radiologists (Great Britain)).

ER and HER2 expression are positively correlated in HER2 non-overexpressing breast cancer

J. Cuzick, M. Dowsett, A. Harris, 2009, Breast Cancer Research.

Antiproliferative Effect of Lapatinib in HER2-Positive and HER2-Negative/HER3-High Breast Cancer: Results of the Presurgical Randomized MAPLE Trial (CRUK E/06/039)

M. Dowsett, S. Johnston, I. Smith, 2014, Clinical Cancer Research.

Counselling is not appropriate for all patients with cancer

A. Horwich, J. Bliss, C. Moynihan, 1999, British medical journal.

Can Interrogation of Tumour Characteristics Lead us to Safely Omit Adjuvant Radiotherapy in Patients with Early Breast Cancer?

C. Coles, A. Kirby, I. Bhattacharya, 2018, Clinical oncology (Royal College of Radiologists (Great Britain)).

CorrigendumCorrigendum to “The impact of age and clinical factors on quality of life in early breast cancer: An analysis of 2208 women recruited to the UK START Trial (Standardisation of Breast Radiotherapy Trial)”: [Breast 16 (2007) 241–251]

J. Haviland, J. Bliss, J. Mills, 2008 .

ER and HER 2 expression are positively correlated in HER 2 non-overexpressing breast cancer

Hern, J. Cuzick, M. Dowsett, 2016 .

Randomized phase III trials of adjuvant FAMTX or FEMTX compared with surgery alone in resected gastric cancer. A combined analysis of the EORTC GI Group and the ICCG.

A. Tres, E. Van Cutsem, D. Crivellari, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

Improving the quality of data in clinical trials in cancer. COMPACT Steering Committee.

T N Bryant, R M Greenwood, R. Greenwood, 1991, British Journal of Cancer.

Neoadjuvant vinorelbine/epirubicin (VE) versus standard adriamycin/cyclophosphamide (AC) in operable breast cancer: analysis of response and tolerability in a randomised phase III trial (TOPIC 2).

R. Laing, T. Hickish, S. Ebbs, 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

A novel continuous infusional 5-fluorouracil-based chemotherapy regimen compared with conventional chemotherapy in the neo-adjuvant treatment of early breast cancer: 5 year results of the TOPIC trial.

R. Laing, A. Howell, T. Hickish, 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

Five-fraction Radiotherapy for Breast Cancer: FAST-Forward to Implementation.

J. Yarnold, N. Somaiah, A. Kirby, 2021, Clinics in oncology.

Clinical impact of IMPORT HIGH trial (CRUK/06/003) on breast radiotherapy practices in the United Kingdom.

John R Yarnold, Laura Ciurlionis, J. Yarnold, 2015, The British journal of radiology.

Adjuvant chemotherapy in older women (ACTION) study – what did we learn from the pilot phase?

L. Fallowfield, A. Makris, D. Cameron, 2011, British Journal of Cancer.

Mitozantrone and methotrexate chemotherapy with and without mitomycin C in the treatment of advanced breast cancer: a randomised clinical trial.

R. Coombes, J. Bliss, R. Stein, 1992, European journal of cancer.

Abstract GS1-03: Peri-operative aromatase inhibitor treatment in determining or predicting longterm outcome in early breast cancer – The POETIC* Trial (CRUK/07/015)

M. Dowsett, J. Robertson, E. Mallon, 2018 .

Reply to Goodare et al. Re: Do Patient-reported Outcome Measures Agree with Clinical and Photographic Assessments of Normal Tissue Effects after Breast Radiotherapy?

J. Yarnold, M. Wilcox, J. Haviland, 2016, Clinical oncology (Royal College of Radiologists (Great Britain)).

The MARS feasibility trial : Conclusions not supported by data - Authors' reply

J. Peto, T. Treasure, D. Landau, 2011 .

Can patient-reported outcomes be used instead of clinician-reported outcomes and photographs as primary endpoints of late normal tissue effects in breast radiotherapy trials? Results from the IMPORT LOW trial

J. Yarnold, C. Coles, A. Kirby, 2019, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Design and rationale of a randomised comparison of cyclophosphamide, methotrexate and fluorouracil vs fluorouracil, epirubicin and cyclophosphamide in node-positive premenopausal women with operable breast cancer. A trial of the International Collaborative Cancer Group (ICCG).

R. Coombes, J. Bliss, M. Marty, 1993, Drugs.

Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT)

I. Ellis, M. Dowsett, P. Ellis, 2009 .

In Reply [to Neven et al] [Letter]

I. Ellis, M. Dowsett, J. Bartlett, 2008 .

Combined Perioperative Lapatinib and Trastuzumab in Early HER2-Positive Breast Cancer Identifies Early Responders: Randomized UK EPHOS-B Trial Long-Term Results

E. Rakha, D. Cameron, D. Dodwell, 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

Abstract P5-14-04: Effects of dose-dense chemotherapy on recurrence and cause-specific mortality in women with early breast cancer: A meta-analysis of individual patient data from randomised trials

R. Gray, R. Peto, L. Norton, 2017 .

Abstract GS1-08: CCTGMA.32, a phase III randomized double-blind placebo controlled adjuvant trial of metformin (MET) vs placebo (PLAC) in early breast cancer (BC): Results of the primary efficacy analysis (clinical trials.gov NCT01101438)

Bingshu E. Chen, T. Whelan, K. Gelmon, 2022, Cancer Research.

Clinico-pathologic relationships with Ki67 and its change with short-term aromatase inhibitor treatment in primary ER + breast cancer: further results from the POETIC trial (CRUK/07/015)

M. Dowsett, L. Zabaglo, E. Mallon, 2023, Breast Cancer Research.

Randomized Phase II Study Evaluating Palbociclib in Addition to Letrozole as Neoadjuvant Therapy in Estrogen Receptor – Positive Early Breast Cancer

Maggie, Morden., M. Dowsett, 2019 .

Randomized, phase III trial of sequential epirubicin and docetaxel versus epirubicin alone in postmenopausal patients with node-positive breast cancer.

M. Espié, R. Coombes, A. Tres, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Modelling the cost-effectiveness of first, second and third generation polychemotherapy regimens in women with early breast cancer who have differing prognoses.

M. Sculpher, H. Earl, J. Yarnold, 2009 .

Impact on quality of life (QoL) of FEC-T compared with FEC or E-CMF: UK Taxotere as Adjuvant Chemotherapy Trial (TACT) 2-year follow-up

D. Cameron, A. Ridolfi, E. Hall, 2008 .

Patients' views of distress & interference with daily activities due to side effects in the TACT (Taxotere as Adjuvant ChemoTherapy) trial

D. Cameron, A. Ridolfi, E. Hall, 2008 .

Fast recruiting clinical trials – a Utopian dream or logistical nightmare?

J. Bliss, P. Ellis, L. Johnson, 2005, British Journal of Cancer.

First results of the randomised UK FAST Trial of radiotherapy hypofractionation for treatment of early breast cancer (CRUKE/04/015).

Joanne S Haviland, John R Yarnold, J. Yarnold, 2011, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Influence of psychological response on breast cancer survival: 10-year follow-up of a population-based cohort.

M. Watson, J. Haviland, J. Bliss, 2005, European journal of cancer.

Dose-escalated simultaneous integrated boost radiotherapy in early breast cancer (IMPORT HIGH): a multicentre, phase 3, non-inferiority, open-label, randomised controlled trial

E. Sawyer, J. Yarnold, C. Coles, 2023, The Lancet.

Evaluation of a method for grading late photographic change in breast appearance after radiotherapy for early breast cancer.

D. Tait, J. Yarnold, L. Gothard, 2008, Clinical oncology (Royal College of Radiologists (Great Britain)).

A comparison of adjuvant psychological therapy and supportive counselling in patients with cancer

J. Bliss, S. Greer, M. Law, 1998, Psycho-oncology.

Aromatase Inhibitors for treatment of metastatic breast cancer

L. Gibson, J. Bliss, 2001 .

Evaluation of applying IHC4 as a prognostic model in the translational study of Intergroup Exemestane Study (IES): PathIES

P. Lønning, M. Cheang, V. Speirs, 2017, Breast Cancer Research and Treatment.

Analgesics in cancer pain: current practice and beliefs.

J. Bliss, P. Hoskin, G. Hanks, 1991, British Journal of Cancer.

OC-0135 CAN PATIENT REPORTED OUTCOME MEASURES REPLACE CLINICAL ASSESSMENTS IN BREAST RADIOTHERAPY TRIALS?

J. Yarnold, J. Haviland, J. Bliss, 2012 .

Implementation of platform trials in the COVID-19 pandemic: A rapid review

C. Yap, J. Bliss, A. Vanderbeek, 2021, Contemporary Clinical Trials.

0186 Treatment options for locally advanced or metastatic triple negative breast cancer: A survey of current UK practice

A. Tutt, J. Bliss, L. Kilburn, 2009 .

Abstract GS3-03: A phase III multicentre double blind randomised trial of celecoxib versus placebo in primary breast cancer patients (REACT – Randomised EuropeAn celecoxib trial)

M. Rezai, C. Denkert, A. Makris, 2018 .

Randomised comparison of a 13 fraction schedule with a conventional 25 fraction schedule of radiotherapy after local excision of early breast cancer: preliminary analysis

J. Yarnold, J. Bliss, J. Owen, 1993 .

53 Principal results of the feasibility phase of the Mesothelioma and Radical Surgery trial (MARS-feasibility)

J. Peto, T. Treasure, J. Bliss, 2011 .

Prognostic and predictive implications of the intrinsic subtypes and gene expression signatures in early-stage HER2+ breast cancer: A pooled analysis of CALGB 40601, NeoALTTO, and NSABP B-41 trials.

C. Perou, K. Hoadley, C. Sotiriou, 2022, Journal of Clinical Oncology.

Anthracycline-containing and taxane-containing chemotherapy for early-stage operable breast cancer: a patient-level meta-analysis of 100 000 women from 86 randomised trials

Bingshu E. Chen, R. Gray, P. Lønning, 2023, The Lancet.

Everolimus Added to Adjuvant Endocrine Therapy in Patients With High-Risk Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Primary Breast Cancer

F. Penault-Llorca, F. André, J. Lemonnier, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomised trial of epirubicin versus fluorouracil in advanced gastric cancer. An International Collaborative Cancer Group (ICCG) study.

D. Amadori, R. Coombes, H. Rauschecker, 1994, Annals of oncology : official journal of the European Society for Medical Oncology.

Clinical Trials From the Other Side: Lessons Learned by a Clinician Venturing Into a Clinical Trials Unit.

I. Bhattacharya, J. Bliss, 2019, Clinical oncology (Royal College of Radiologists (Great Britain)).

Patient advocate involvement in the design and conduct of breast cancer clinical trials requiring the collection of multiple biopsies

M. Wilcox, I. Bhattacharya, J. Haviland, 2018, Research Involvement and Engagement.

Evaluation of adjuvant psychological therapy in patients with testicular cancer: randomised controlled trial

A. Horwich, J. Bliss, C. Moynihan, 1998, BMJ.

A method for assessing the quality of life of cancer patients: replication of the factor structure.

P. Selby, J. Bliss, T. Powles, 1992, British Journal of Cancer.

Oral contraceptives and survival in breast cancer.

J. Bliss, J. Gazet, C. Chilvers, 1987, British Journal of Cancer.

Breast cancer and hormone-replacement therapy: the Million Women Study

J. Bliss, R. Gray, 2003, The Lancet.

Hypofractionation for early breast cancer: First results of the UK standardization of breast radiotherapy (START) trials

J. Yarnold, J. Dewar, J. Haviland, 2007 .

Management of breast cancer Refer women to multidisciplinary breast clinics

H. Earl, J. Yarnold, S. Kaye, 1994, BMJ.

Activity of cediranib in alveolar soft part sarcoma (ASPS) confirmed by CASPS (cediranib in ASPS), an international, randomised phase II trial (C2130/A12118).

I. Judson, B. Seddon, J. Bliss, 2017 .

Impact on quality of life (QL) during chemotherapy (CT) of FEC-T compared to FEC or E-CMF: Results from the UK NCRI Taxotere as Adjuvant Chemotherapy Trial (TACT)

D. Cameron, E. Hall, J. Bliss, 2005 .

Dose-escalated simultaneous integrated boost radiotherapy in early breast cancer (IMPORT HIGH): a multicentre, phase 3, non-inferiority, open-label, randomised controlled trial

E. Sawyer, J. Yarnold, C. Coles, 2023, The Lancet.

Major Impact of Sampling Methodology on Gene Expression in Estrogen Receptor–Positive Breast Cancer

M. Dowsett, E. Mallon, I. Smith, 2018, JNCI cancer spectrum.

FEASIBILITY PHASE OF THE MESOTHELIOMA AND RADICAL SURGERY (MARS) RANDOMISED CONTROLLED TRIAL COMPARING EXTRA-PLEURAL PNEUMONECTOMY (EPP) WITH NO EPP IN PATIENTS WITH MALIGNANT PLEURAL MESOTHELIOMA

J. Peto, T. Treasure, D. Landau, 2011 .

Molecular profiling of aromatase inhibitor sensitive and resistant ER+HER2- postmenopausal breast cancers

M. Salto‐Tellez, P. Maxwell, M. Dowsett, 2023, Nature communications.

Abstract OT1-06-03: The plasmaMATCH trial: A multiple parallel cohort, open-label, multi-centre phase II clinical trial of ctDNA screening to direct targeted therapies in patients with advanced breast cancer (CRUK/15/010)

A. Wardley, R. Roylance, N. Turner, 2018 .

Concordance of intrinsic subtyping and risk of recurrence (ROR) scores between matched primary and metastatic tissue from Triple Negative Breast Cancer Trial (TNT).

M. Dowsett, P. Ellis, M. Cheang, 2015 .

J. Peto, T. Treasure, D. Landau, 2011, The Lancet. Oncology.

Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials)†.

S Michiels, B Asselain, J Bogaerts, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Adjuvant psychological therapy for patients with cancer: a prospective randomised trial.

M. Watson, J. Bliss, S. Greer, 1992, BMJ.

Survival and safety of exemestane versus tamoxifen after 2–3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial

P. Lønning, J. Forbes, R. Coombes, 2007, The Lancet.

Influence of psychological response on survival in breast cancer: a population-based cohort study

M. Watson, J. Haviland, J. Bliss, 1999, The Lancet.

Abstract PD5-03: PD5-03 Comparison of a personalized sequencing assay and digital PCR for circulating tumor DNA based Molecular Residual Disease detection in early-stage triple negative breast cancer in the cTRAK-TN trial

T. Hickish, A. Wardley, N. Turner, 2023, Cancer Research.

Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials

S. Steinberg, E. Rutgers, E. Winer, 2018, The Lancet. Oncology.

Principal results of the cancer of the ovary abiraterone trial (CORAL): A phase II study of abiraterone in patients with recurrent epithelial ovarian cancer (CRUKE/12/052)

M. Dowsett, M. Gore, G. Rustin, 2016 .

Plasma ESR 1 Mutations and the Treatment of Estrogen Receptor – Positive Advanced Breast Cancer

M. Dowsett, S. Loi, S. Loibl, 2016 .

A Randomized Trial Of Exemestane After Two To Three Years Of Tamoxifen Therapy In Postmenopausal Women With Primary Breast Cancer.

P. Lønning, L. Fallowfield, L. Gibson, 2004 .

Evaluation of applying IHC4 as a prognostic model in the translational study of Intergroup Exemestane Study (IES): PathIES

P. Lønning, M. Cheang, V. Speirs, 2017, Breast Cancer Research and Treatment.

Homologous recombination DNA repair deficiency and PARP inhibition activity in primary triple negative breast cancer

M. Dowsett, S. Nik-Zainal, A. Tutt, 2020, Nature Communications.

Risk of cutaneous melanoma associated with pigmentation characteristics and freckling: systematic overview of 10 case-control studies. The International Melanoma Analysis Group (IMAGE).

E. Holly, A. Green, R. MacKie, 1995, International journal of cancer.

Abstract S3-3: The UK TACT2 Trial: comparison of standard vs accelerated epirubicin in patients requiring chemotherapy for early breast cancer (EBC) (CRUK/05/019)

H. Earl, J. Bartlett, D. Cameron, 2012 .

Analgesics in cancer pain. an investigation of physicians' preference and use

J. Bliss, P. Hoskin, G. Hanks, 1990, Pain.

Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial

A. Ashworth, C. Perou, N. Rahman, 2018, Nature Medicine.

Mesothelioma and radical surgery trial (MARS): the feasibility study process

J. Peto, T. Treasure, J. Bliss, 2009 .

Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials

E. Rutgers, E. Winer, J. Cuzick, 2015, The Lancet.

Ipsilateral breast tumor relapse: local recurrence versus new primary tumor and the effect of whole-breast radiotherapy on the rate of new primaries.

J. Yarnold, J. Haviland, J. Bliss, 2011, International journal of radiation oncology, biology, physics.

Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women.

L. Gibson, J. Bliss, D. Lawrence, 2009, The Cochrane database of systematic reviews.

Impact of BMI in Patients With Early Hormone Receptor–Positive Breast Cancer Receiving Endocrine Therapy With or Without Palbociclib in the PALLAS Trial

K. Gelmon, M. Gnant, C. Isaacs, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

J. Bergh, R. Peto, L. Norton, 2018 .

Effects of perioperative lapatinib and trastuzumab, alone and in combination, in early HER2+breast cancer - the UK EPHOS-B trial (CRUK/08/002)

D. Cameron, D. Dodwell, K. Horgan, 2016 .

Integrated Multimodal Analyses of DNA Damage Response and Immune Markers as Predictors of Response in Metastatic Triple-Negative Breast Cancer in the TNT Trial (NCT00532727)

C. Perou, K. Hoadley, S. Loi, 2023, Clinical cancer research : an official journal of the American Association for Cancer Research.